Skip to main content

Table 4 Characteristics of five studies (nine papers) investigating the association between COMT gene and opioid response and/or side effects included in the systematic review

From: Opioid response in paediatric cancer patients and the Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene: an Italian study on 87 cancer children and a systematic review

Study name, [ref] Study design Patients characteristics Opioid administered Data M/F Mean Age (years)
Opioid dose Pain Side effects
EPOS study European observational study Cancer pain patients Morphine, methadone, fentanyl, hydromprphone, buprenorphine, ketobemidone, oxycodone      
[18] (Klepstad, 2011)   2201 Caucasians X    1154/1047 62.4
[19] (Barratt, 2014)a   667 subjects treated with transdermal fentanyl     334/342 Median: 64
[20] (Barratt, 2015)b   468 Caucasian subjects treated with transdermal fentanyl   X X 218/250 Median: 64
[21] (Laugsand, 2011)   1579 subjects not receiving chemotherapy and with information on nausea and vomiting    X 850/729 61.9
[22] Matsuoka, 2012 Japanese observational study 48 Opioid-treatment-naïve cancer patients Morphine X    25/23 69.0
[23, 24] Rakvåg, 2005–2008 Norwegian observational study 207 Cancer pain Caucasian patients Morphine X X X 117/90 63.2
[28] Ross, 2008 United Kingdom case-control study 228 Cancer pain patients Morphine, Oxycodone, fentanyl, methadone   X X 106/122 57.2
[26] Chatti, 2016 Tunisian observational study 129 Cancer pain patients Morphine X    63/66 Number of patients for each age group:
17-25 yrs.: 12
26-45 yrs.: 50
46-65 yrs.: 67
  1. aBarratt, 2014 [19] was a subgroup analysis of Klepstad, 2011 [18] (i.e. 676 subjects treated with transdermal fentanyl)
  2. bBarratt, 2015 [20] was a subgroup analysis of Barratt, 2014 [19] (i.e. 468 Caucasian subjects treated only with transdermal fentanyl)